- Corporate Officers - C
- Chardonnet Laurent
Insider Trading History of Chardonnet Laurent
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Chardonnet Laurent since 2008.
This trader's CIK number is 1329010.
At the time of last reporting, Chardonnet Laurent was the Chief Financial Officer of Prelude Therapeutics Inc. (stock ticker symbol PRLD).
Also see all insider trading activities at Prelude Therapeutics Inc.
Note that in the past
Chardonnet Laurent also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Prelude Therapeutics Inc (PRLD) by Chardonnet Laurent
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2023 | PRLD | 5,000 | $27,500 | 0 | $0 | 0 | $0 |
| 2022 | PRLD | 20,000 | $89,900 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Incyte Corp (INCY) by Chardonnet Laurent
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2015 | INCY | 0 | $0 | 113,776 | $10,653,984 | 113,776 | $1,825,308 |
| 2014 | INCY | 0 | $0 | 134,392 | $8,381,409 | 132,334 | $1,094,123 |
| 2013 | INCY | 0 | $0 | 44,834 | $1,672,907 | 41,800 | $342,049 |
| 2012 | INCY | 0 | $0 | 86,342 | $2,099,343 | 72,366 | $507,941 |
| 2011 | INCY | 0 | $0 | 70,343 | $1,275,880 | 65,000 | $296,150 |
| 2010 | INCY | 0 | $0 | 15,618 | $219,667 | 0 | $0 |
| 2008 | INCY | 8,000 | $21,640 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Axcella Health Inc. (AXLA) by Chardonnet Laurent
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2020 | AXLA | 3,665 | $18,097 | 0 | $0 | 0 | $0 |
Insider trading activities at 3 companies by Chardonnet Laurent:
1. Prelude Therapeutics Inc (PRLD)
2. Incyte Corp (INCY)
3. Axcella Health Inc. (AXLA)
Table 1. Insider trading of Prelude Therapeutics Inc (PRLD) by Chardonnet Laurent
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2023-05-23 | PRLD | Buy | 5,000 | 5.50 | 27,500 |
| 2022-12-08 | PRLD | Buy | 10,000 | 4.76 | 47,600 |
| 2022-06-01 | PRLD | Buy | 10,000 | 4.23 | 42,300 |
Table 2. Insider trading of Incyte Corp (INCY) by Chardonnet Laurent
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2015-03-30 | INCY | Sale | 113,776 | 93.64 | 10,653,984 |
| 2015-03-30 | INCY | Option Ex | 113,776 | 16.04 | 1,825,308 |
| 2014-05-12 | INCY | Sale | 2,058 | 54.00 | 111,132 |
| 2014-05-02 | INCY | Sale | 34,000 | 51.55 | 1,752,700 |
| 2014-05-02 | INCY | Option Ex | 34,000 | 9.41 | 319,940 |
| 2014-02-13 | INCY | Sale | 98,334 | 66.28 | 6,517,577 |
| 2014-02-13 | INCY | Option Ex | 98,334 | 7.87 | 774,183 |
| 2013-09-05 | INCY | Option Ex | 41,800 | 8.18 | 342,049 |
| 2013-09-05 | INCY | Sale | 8,767 | 34.90 | 305,968 |
| 2013-09-09 | INCY | Sale | 36,067 | 37.90 | 1,366,939 |
| 2012-07-05 | INCY | Option Ex | 35,700 | 7.09 | 253,113 |
| 2012-07-05 | INCY | Sale | 35,700 | 25.11 | 896,605 |
| 2012-07-02 | INCY | Sale | 36,666 | 24.15 | 885,483 |
| 2012-07-02 | INCY | Option Ex | 36,666 | 6.95 | 254,828 |
| 2012-05-01 | INCY | Sale | 13,976 | 22.70 | 317,255 |
| 2011-06-21 | INCY | Sale | 40,000 | 18.64 | 745,600 |
| 2011-06-21 | INCY | Option Ex | 40,000 | 5.46 | 218,400 |
| 2011-05-06 | INCY | Sale | 5,343 | 19.55 | 104,455 |
| 2011-04-08 | INCY | Sale | 25,000 | 17.03 | 425,825 |
| 2011-04-08 | INCY | Option Ex | 25,000 | 3.11 | 77,750 |
| 2010-08-09 | INCY | Sale | 15,618 | 14.06 | 219,667 |
| 2008-11-20 | INCY | Buy | 8,000 | 2.71 | 21,640 |
Table 3. Insider trading of Axcella Health Inc. (AXLA) by Chardonnet Laurent
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2020-01-31 | AXLA | Buy | 3,000 | 4.94 | 14,820 |
| 2020-01-24 | AXLA | Buy | 313 | 4.92 | 1,539 |
| 2020-01-27 | AXLA | Buy | 352 | 4.94 | 1,738 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Chardonnet Laurent
(Chief Financial Officer of Prelude Therapeutics Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.